Patritumab

Generic Name
Patritumab
Brand Names
-
Drug Type
Biotech
Chemical Formula
-
CAS Number
1262787-83-6
Unique Ingredient Identifier
86780VJI1Q
Background

Patritumab has been used in trials studying the treatment of LUNG CANCER, Solid Tumors, Neoplasms by Site, Head and Neck Neoplasms, and Non-small Cell Lung Cancer, among others.

Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

Patritumab With Cetuximab and a Platinum Agent for Squamous Cell Carcinoma (Cancer) of the Head and Neck (SCCHN )

First Posted Date
2015-12-17
Last Posted Date
2019-01-07
Lead Sponsor
Daiichi Sankyo
Target Recruit Count
87
Registration Number
NCT02633800
Locations
πŸ‡«πŸ‡·

Hopital Croix-Rousse, Lyon, France

πŸ‡΅πŸ‡±

Centrum Onkologii im. Prof. Franciszka Lukaszczyka w Bydgoszczy, Bydgoszcz, Poland

πŸ‡§πŸ‡ͺ

Institut Jules Bordet, Brussels, Belgium

and more 29 locations

Patritumab With Cetuximab and a Platinum Containing Therapy for Patients With Head and Neck Cancer

First Posted Date
2015-01-30
Last Posted Date
2018-09-11
Lead Sponsor
Daiichi Sankyo
Target Recruit Count
15
Registration Number
NCT02350712
Locations
πŸ‡¬πŸ‡§

University College London Hospital, London, United Kingdom

πŸ‡¬πŸ‡§

The Royal Marsden Hospital, London, United Kingdom

Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung)

First Posted Date
2014-05-08
Last Posted Date
2018-01-23
Lead Sponsor
Daiichi Sankyo
Target Recruit Count
145
Registration Number
NCT02134015

Study to Assess Pharmacokinetics, Immunogenicity and Safety/Tolerability of Patritumab (U3-1287)

Phase 1
Completed
Conditions
Solid Tumors
Interventions
Drug: patritumab
First Posted Date
2013-10-08
Last Posted Date
2014-05-14
Lead Sponsor
Daiichi Sankyo
Target Recruit Count
17
Registration Number
NCT01957280
Β© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy